AI assistant
Summit Therapeutics Inc. — Director's Dealing 2024
Apr 15, 2024
30436_dirs_2024-04-15_53ef5479-e600-4db9-b170-50e33b2a9da4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2024-04-11
Reporting Person: Ronaghi Mostafa (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-04-11 | Stock Option (right to buy) | $4.03 | A | 200000 | Acquired | 2034-04-11 | Common Stock (200000) | Direct |
| 2024-04-11 | Stock Option (right to buy) | $4.03 | A | 25315 | Acquired | 2034-04-11 | Common Stock (25315) | Direct |
Footnotes
F1: The option was granted on April 11, 2024. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on April 11, 2025, subject to the director remaining as a non-salaried director on each such vesting date.
F2: Not applicable.
F3: The option was granted on April 11, 2024 and represents a pro rata amount of the annual 35,000 option board grant based approximately on the number of days the reporting person is anticipated to serve as a director in 2024. The shares underlying the option are scheduled to vest in full on December 31, 2024, subject to the director remaining as a non-salaried director on such vesting date.